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Highlights 59 
x A set of only four highly tissue specific tDMR markers is sufficient for reliable and robust 60 
identification of semen, saliva, venous blood, and menstrual blood.  61 
x A multiplex assay was developed for simultaneous detection of these fluids. 62 
x The multiplex assay can be applied to single source fluids as well as mixtures.  63 
x The components of mock crime scene stains were successfully identified. 64 
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Abstract 69 
Potential forensic use of tissue-specific DNA methylation markers has recently been discussed for the 70 
identification of the biological source of a stain. In this study 13 promising markers were evaluated to 71 
identify suitable candidate markers for the development of a robust and reliable multiplex assay. The 72 
results of this study suggest that a combination of only four highly informative markers will be enough for 73 
clear body fluid identification. A multiplex assay was developed for the identification of menstrual blood, 74 
saliva, semen, and venous blood. This assay was successfully applied to the identification of these body 75 
fluids in mixtures and crime scene stains. The multiplex assay aids in the identification of not only single 76 
source body fluids but also of body fluid mixtures. The main advantage of using DNA methylation assays 77 
over alternative tests is that it can be applied at a later time point in the investigative process since testing 78 
is possible even after DNA analysis. 79 
 80 
1. Introduction 81 
Identifying the biological source of a crime scene stain can be crucial for the course and outcome of police 82 
investigations, and aid in crime scene reconstruction. Due to the importance of body fluid identification in 83 
forensic settings, various methods have been developed and improved for this purpose over the last 84 
decades [1]. Many such tests rely on catalytic, enzymatic or immunological activities [2], and have been 85 
used successfully in identifying venous blood [3], saliva, semen [4], and menstrual blood [5,6]. They are, 86 
however, presumptive in nature, and designed to detect one specific body fluid, requiring the investigator 87 
to perform a test based on the fluid that is most likely to be present. An alternative approach is the 88 
analysis of tissue-specific messenger RNA (mRNA) [7,8] and microRNA [9] as these assays do not cross 89 
react with non-biological materials and allow for simultaneous testing of several body fluids [10]. Yet RNA-90 
based assays suffer from the fact that RNA is less stable than DNA and require additional consumption of 91 
samples, unless the RNA is co-extracted with DNA. 92 
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Recently, potential forensic use of DNA epigenetic markers has been discussed for the identification of the 93 
biological source of a stain [8,11±13]. The term epigenetics refers to regulatory mechanisms of the 94 
genome that, in contrast to genetic variations, control cell dynamics and gene regulation without modifying 95 
the sequence of the DNA. One of several epigenetic mechanisms that cells use to control gene 96 
expression is DNA methylation. DNA methylation is the chemical modification of the DNA in which a 97 
methyl group (-CH3 LVDGGHG WR WKH¶SRVLWLRQRI WKHS\ULPLGLQH ULQJRIF\WRVLQHV LQ&S* dinucleotides 98 
[14], and is generally understood as an inhibitor of DNA transcription [15]. The theory that DNA 99 
methylation patterns may be used for the identification of various body fluids is based on the finding that 100 
the expression of genes can be tissue specific. DNA methylation is fundamental in the control of cell 101 
growth and cellular differentiation and thus, different cell types are specifically fingerprinted through their 102 
methylation profile. These methylation profiles believed to be tissue-specific are called ÄWLVVXH-specific 103 
GLIIHUHQWLDOO\PHWK\ODWHGUHJLRQV³W'05V7KHSRWHQWLDOXVHRIW'05VIRUWKHLGHQWLILFDWLRQRIERG\IOX ids 104 
has been indicated by recent advances in whole genome epigenetic analyses and current research in 105 
forensic science suggested the use of tDMRs within the human genome as possible marker for human 106 
specific body fluid identification [8,16].  107 
Methylation assays show several advantages over conventional presumptive tests such as high sensitivity 108 
and specificity to avoid cross-reactivity with other species or materials. Moreover, DNA as a target is 109 
particularly appealing as DNA is more stable than RNA, allowing cell identification even in highly degraded 110 
or aged samples. DNA methylation assays are also compatible with other DNA-based methods that are 111 
commonly used in forensic analyses such as DNA extraction, polymerase-chain-reaction (PCR), and the 112 
generation of a DNA profile [8]. Additionally, the development of a multiplex detection assay allows for 113 
simultaneous detection of various body fluids while conventional presumptive tests target only one tissue 114 
type at a time and require the analyst to make previous assumptions regarding the type of tissue present 115 
in a trace. 116 
It is to be expected that methylation analysis will soon become an important tool for the forensic 117 
investigation of crime, and therefore, it is essential to develop appropriate detection assays that allow the 118 
fast, robust and ultrasensitive detection of differentially methylated DNA sequences.  119 
In our study 13 markers were evaluated in singleplex assays during initial testing to identify suitable 120 
candidate markers for the identification of human body fluids. A minimum of distinctive markers was then 121 
combined to develop a robust and reliable multiplex assay, with as few as possible markers. Analyzed 122 
body fluids were menstrual blood from days 1, 2, and 3 of the menses, saliva, semen, and venous blood. 123 
2. Materials and Methods 124 
2.1 Selection of appropriate tDMRs for body fluid identification  125 
A literature review was performed to identify the most promising candidate markers for the identification of 126 
semen, saliva, venous blood, and menstrual blood. Main criterion for selection was the tissue specificity of 127 
methylation states. A total of 13 candidate markers were selected for initial testing: Four for the detection 128 
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of menstrual blood [17±20], one for the detection of saliva [20], six for the detection of semen [17±20], and 129 
two for the detection of venous blood [19,20] (Table S1). Menstrual blood markers were intended to 130 
identify vaginal fluid in the original studies [17±20] and tested for their applicability to detect menstrual 131 
blood in this study.  132 
2.2 Sample collection and preparation 133 
Body fluid samples were collected from 43 volunteers (16 females and 27 males) with informed consent 134 
using procedures approved by the local ethical committee (Ethik-Kommission der Ärztekammer 135 
Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster). Venous blood (n = 13) was 136 
collected by venipuncture, and semen (n = 17) was collected in plastic cups. Both fluids were stored 137 
frozen in 200 µl aliquots. Menstrual blood was obtained using sterile cotton swabs on the first three days 138 
of the menses (n = 10 for each day), dried, and stored at room temperature. Saliva (n = 18) was collected 139 
by cheek swabs using sterile cotton swabs and by discharging saliva into a tube. The cotton swabs were 140 
dried, and stored at room temperature, and liquid saliva was stored frozen in 200 µl aliquots. For the initial 141 
investigation of the markers in singleplex nine menstrual blood samples, ten saliva samples, six semen 142 
samples, and ten venous blood samples were used. The sample set was increased from 9 to 30 143 
menstrual blood, 10 to 18 saliva, 6 to 17 semen, and 10 to 13 venous blood samples for the development 144 
of the final multiplex assay.  145 
'1$ ZDV H[WUDFWHG XVLQJ WKH '1$ ,4 &DVHZRUN 3UR .LW RQ WKH 0D[ZHOO  )RUHQVLF ,QVWUXPHQW146 
(Promega, Mannheim, Germany). Half a cotton swab per menstrual blood and saliva sample, and 3 µl of 147 
each venous blood and semen sample were extracted in 350 µl of Casework Extraction Buffer that was 148 
prepped with 19 µl of Proteinase K (Casework Extraction Kit, Promega). Samples were incubated for 1h at 149 
70°C and subsequently lysed in 200 µl lysis buffer. DNA was eluted in 50 µl elution buffer, and quantified 150 
XVLQJ 3URPHJD¶V 3RZHU4XDQW 6\VWHP with 1 µl sample, 5 µl 2X Master Mix, 0.5 µl 20X 151 
Primer/Probe/IPC Mix, and HPLC-grade water to a reaction volume of 10 µl. DNA concentration of the 152 
samples was adjusted to the optimal DNA input for bisulfite treatment of 200 to 500 ng.  153 
2.3 Bisulfite treatment, PCR, and methylation SNaPshot  154 
%LVXOILWH WUHDWPHQW ZDV SHUIRUPHG XVLQJ WKH (= '1$ 0HWK\ODWLRQ .LW =\PR 5HVHDUFK )UHLEXUJ155 
*HUPDQ\ DFFRUGLQJ WR PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV Bisulfite conversion efficiency was calculated 156 
by measuring genomic DNA content before and after bisulfite treatment using the PowerQuant® system 157 
as described above.  158 
Bisulfite-converted DNA was amplified in a 12.5 µl reaction volume containing 1 µl template DNA, 1.25 µl 159 
dNTPs (100 mM), 1.5 µl MgCl2 (25 mM), 0.5 µl AmpliTaq Gold® DNA Polymerase and 1.25 µl AmpliTaq 160 
Gold Buffer 10 x (5U/µl) Thermo Fisher Scientific, Darmstadt, Germany), and 0.2 µl BSA (MoBiTec, 161 
Göttingen, Germany). PCR primers for the amplification of bisulfite-converted DNA and single-base 162 
extension (SBE) primers for the target CpGs were slightly modified using sequences from previous reports 163 
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[17±20] (Tables S2 and S3). PCR primers were designed to amplify bisulfite-treated DNA. All primers 164 
were synthesized by and purchased from Biomers (Germany) and diluted in water to reach a 165 
concentration of 100 pmol/µl. 166 
Primer reactivity and marker performance were tested in singleplex reactions. Subsequently, a multiplex 167 
reaction was developed using the most tissue specific markers. 168 
For the initial testing of all markers, primer concentrations ranged between 0.4 - 8 µM. For the final 169 
multiplex PCR assay primer concentrations were optimized to concentrations ranging from 0.16 - 53.3 µM 170 
(see supplementary Table S2 and S3 for details). PCR was performed under the following conditions: 171 
96°C for 10 min; 30 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min; followed by a final 172 
extension at 60°C for 1 hour. PCR products were purified by adding 0.025 µl of exonuclease I (New 173 
England Biolabs, Frankfurt, Germany) and 1.25 µl of rAPid Alkaline Phosphatase (Roche Diagnostics, 174 
Mannheim, Germany) to each sample under the following conditions: 37°C for 95 min and 78°C for 175 
15 min. The following SBE UHDFWLRQ ZDV SHUIRUPHG XVLQJ 61D3VKRW WHFKQRORJ\ 7KHUPR )LVKHU176 
Scientific): 1 µl of purified PCR products, 0.36 µM of SBE primers, and 1.25 µl of SNaPshot® Ready 177 
Reaction Mix, and HPLC-grade water were used to a reaction volume of 5.5 µl under the following 178 
conditions: 25 cycles of 96°C for 10 sec, 55°C for 5 sec, and 60°C for 30 sec; and a final extension at 179 
60°C for 10 min. SBE products were purified with 1 µl of rAPid Alkaline Phosphatase under the following 180 
conditions: 37°C for 75 min and 78°C for 15 min. To 1 µl of purified SBE product 10 µl of Hi-'L-181 
)RUPDPLGH LQFOXGLQJ *HQH6FDQ  /,= 6Lze Standard (Thermo Fisher Scientific) were added, 182 
denatured at 95°C for 3 min, and subsequently analyzed using the 3130 Genetic Analyzer with the 183 
GeneMapper® ID software by Thermo Fisher Scientific.  184 
The multiplex assay was further used for a mixture analysis of fluid venous blood, fluid semen, fluid saliva, 185 
and fluid menstrual blood from day one of the menses. This was done by combining bisulfite-converted 186 
DNA from different body fluids 1:1 to ensure equal DNA concentrations, and analyzing the mixtures using 187 
the developed multiplex assay. Additionally, the multiplex assay was tested for its applicability to crime 188 
scene stains by creating five mock crime scene stains by combining body fluids with different mixing ratios 189 
or as single body fluid to a total volume of up to 12 µl. The mixtures were applied to cellulose swabs and a 190 
small piece was cut out and used for DNA extraction and further analyses described above. The stains 191 
were prepared by an independent laboratory assistant who was not involved in the final interpretation of 192 
their composition. The analyst was given no LQIRUPDWLRQRI WKHPL[WXUHV¶ FRPSRVLWLRQVEHIRUHDQDO\]LQJ193 
the stains using the GeneMapper® ID software. 194 
 195 
2.4 Analysis criteria and statistical analysis  196 
As quality control for the bisulfite-conversion reaction, bisulfite treatment of samples with a bisulfite-197 
conversion efficiency <99.5 % was repeated.  198 
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Two main criteria were set for the assessment of marker performance in singleplex as well as multiplex 199 
assays as follows: Ability to discriminate between body fluids and absence of background noise in the 200 
SNaPshot assay. The ideal marker shows ³on-/off-methylation´ hence hypermethylation in one body fluid 201 
and hypomethylation in all other fluids or vice versa. Ideally the difference in methylation state should be 202 
obvious by visible inspection through analysis of electropherograms rather than being detectable by 203 
application of statistical analysis of large sample sets only. As background noise in electropherogram 204 
signals might interfere with the clear interpretation of the markers only those with a clear baseline and low 205 
to no background noise were included for further investigation.  206 
The relative methylation state (%) of each CpG site was determined by calculating the relative peak height 207 
of the methylated cytosine compared to the combined peak height of the methylated and unmethylated 208 
peaks. The information of the methylation state of each sample was summarized in form of box-whisker-209 
plots, where the box represents 50 % of the data with the band inside indicating the median. The whiskers 210 
each represent 25 % of the data including the maximum and minimum value. Circles represent outliers 211 
and asterisks represent extreme values. 212 
Statistically significant differences between the different body fluids were calculated using the Mann±213 
Whitney U test. A value of p < 0.01 was considered statistically significant, a value of p < 0.001 was 214 
considered highly statistically significant. The calculations and descriptive statistics were carried out 215 
using SPSS version 22. 216 
 217 
3. Results and discussion  218 
3.1 Singleplex SNaPshot assay  219 
The 13 selected markers from relevant literature [17±20] were investigated in singleplex PCR and 220 
SNaPshot assays. The semen-specific marker SE3 produced mainly unspecific signals in the SNaPshot 221 
assay and data was not useable for interpretation (data available on request). All other markers performed 222 
well in the initial singleplex testing and were further investigated in a multiplex assay approach. For the 223 
initial singleplex as well as multiplex development, menstrual blood from day one of the menses was used. 224 
 225 
3.2 Multiplex SNaPshot assay  226 
Figures S1 ± S4 (appendix) show relative methylation (%) for all analyzed markers that were further 227 
investigated in multiplex assays. Only markers that allowed clear differentiation between body fluids were 228 
included in the development of a final multiplex assay: 229 
3.2.1 tDMRs for the detection of menstrual blood  230 
Based on the results of previous reports [17] the tDMR for PFN3 was selected as a menstrual blood-231 
specific marker because of overall lower methylation levels in menstrual blood compared to all other body 232 
fluids. In our study, the methylation state for PFN3 was found to be significantly lower in menstrual blood 233 
compared to saliva and venous blood (p < 0.001), and significantly higher than in semen (p < 0.01). Based 234 
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on these findings, the methylation state of PFN3 might be regarded as specific for menstrual blood; 235 
however, although statistically significant differences were found between menstrual blood and semen, 236 
31 % of the menstrual blood samples expressed a similar methylation state as 50 % of semen samples. 237 
Marker PFN3 was therefore excluded from further analyses (Fig.S1A). The tDMR for VF1, with previously 238 
reported hypermethylation in menstrual blood [20], expressed significant differences in relative methylation 239 
only between menstrual blood and semen and saliva (p  0.001). No statistically significant differences in 240 
methylation states between menstrual blood and venous blood were detected, thus VF1 could not be 241 
validated as menstrual blood-specific and was excluded from further analyses (Fig.S1B). Menstrual blood 242 
expressed significant hypermethylation in VF2 compared to semen, saliva, and blood (p < 0.001). It was 243 
validated as menstrual blood-specific marker confirming previous findings [20] and was added to the final 244 
multiplex assay (Fig.S1C). Marker PRMT2 was previously reported as being hypermethylated in menstrual 245 
blood [17,18]. Our findings strongly supported this with significantly higher methylation in menstrual blood 246 
compared to semen (p < 0.001). Relative methylation in menstrual blood was different from relative 247 
methylation in saliva and venous blood; however, this finding was not statistically significant. 248 
Consequently, this marker was not considered as a menstrual blood-specific marker for the final multiplex 249 
(Fig.S1D).  250 
3.2.2 tDMRs for the detection of saliva   251 
Analysis of SA1 confirmed the results of previous studies [20] as only in saliva it showed almost complete 252 
methylation, while all other body fluids expressed hypomethylation. Differences in relative methylation 253 
were highly significant (p < 0.001), allowing to unambiguously distinguish saliva from semen, venous 254 
blood, and menstrual blood (Fig.S2). Thus, it was validated successfully as a saliva-specific marker and 255 
was added to the final multiplex assay. 256 
3.2.3 tDMRs for the detection of semen 257 
The markers SE1 (Fig.3A) and SE2 (Fig.S3B) were successfully used for the detection of semen as only 258 
semen samples expressed methylation (p < 0.001). These results support previous findings of on-/off-259 
methylation [19,20] and confirm SE1 and SE2 as semen-specific markers. In our study, SE2 showed lower 260 
intersample variation than SE1 and was therefore included in the development of the final multiplex assay. 261 
Relative methylation for the tDMR for marker USP49 (Fig.S1C) was significantly lower in semen compared 262 
to saliva, menstrual blood, and venous blood (p<0.001). Although USP49 was validated [17,18] as a 263 
semen-specific marker statistically, 37 % of the semen samples expressed a similar methylation state as 264 
10% of the venous blood samples, and the marker was not considered for the development of the final 265 
multiplex assay. Previously reported hypomethylation in PRMT2 in semen [17,18] could be confirmed in 266 
this study. Relative methylation in semen was significantly lower than in menstrual blood, venous blood, 267 
and saliva (p < 0.001). High intersample variation in relative methylation amongst venous blood samples 268 
was observed, with 25 % of semen samples expressing a similar methylation state as 5 % of the venous 269 
blood samples (Fig.S3D). Although statistically validated as a semen-specific marker, PRMT2 was not 270 
included in further analyses due to the overlapping results. In the tDMR for DACT1 (Fig.S3E) semen 271 
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expressed significantly lower relative methylation than all other body fluids (p < 0.001) and was 272 
successfully validated as marker for semen detection [17,18]. However, marker SE2, showing 273 
hypermethylation of semen only, was chosen over DACT1. Due to epigenetic reprogramming, 274 
spermatozoa are expected to be hypomethylated [21] making marker SE2 even more interesting for 275 
semen identification since it is a rare example of hypermethylation.  276 
3.2.4 tDMRs for the detection of blood  277 
Marker BL1 (Fig.S4A) expressed statistically significant hypermethylation in venous blood with low to no 278 
methylation in all other body fluids (p   and supported the previously reported properties as a 279 
venous blood-specific marker [20]. While BL2 (Fig.S4B) was expected to be venous blood-specific based 280 
on the results of previous reports [20], our study suggests saliva-specificity as only saliva samples 281 
expressed complete unmethylation. Relative methylation in venous blood was significantly higher than in 282 
saliva (p < 0.001), and menstrual blood (p < 0.01) but slightly lower than in semen (p>0.01). Although this 283 
marker could be validated as blood-specific it was not chosen for the final multiplex as marker BL1 284 
expressed hypermethylation in venous blood only and was therefore considered more reliable.  285 
 286 
3.3 Multiplex SNaPshot assay  287 
For the final multiplex assay only markers for which our findings confirmed results of previous studies and 288 
allowed clear differentiation between body fluids were considered for the development of the final 289 
multiplex assay. We found that only four markers allow complete differentiation between the four body 290 
fluids: These markers showed to be the menstrual-blood specific marker VF2, the saliva-specific marker 291 
SA1, the semen-specific marker SE2, and the venous blood-specific marker BL1.  292 
Figure 1A shows the developed multiplex SNaPshot assay including the four markers, exemplarily for one 293 
sample of each body fluid sample: semen (Fig.1A1), saliva (Fig.1A2), venous blood (Fig.A3), and 294 
menstrual blood of the three days of the menses (MB-1, MB-2, MB-3; Fig.1A4 ± 1A6). The markers were 295 
being detected on the reverse-complementary strand: The blue peak, representing guanine, shows the 296 
methylated portion as methylated cytosine remains unchanged in the bisulfite-conversion reaction and 297 
binds guanine. The green peak, representing adenine, shows the unmethylated portion as unmethylated 298 
cytosine is being converted into uracil in the bisulfite-conversion reaction, amplified as thymine in the PCR 299 
and therefore binding adenine. The selection of the four tDMRs resulted in highly specific methylation 300 
patterns, which allow immediate visual distinction between semen, saliva, venous blood, and menstrual 301 
blood.  302 
Marker VF2 expressed partial to strong methylation in menstrual blood from all three days of the menses 303 
and nearly complete lack of methylation in all other body fluids (p < 0.001; Fig.2A). Menstrual blood 304 
samples showed a clear blue peak in the electropherograms, while saliva, semen, and venous blood 305 
samples showed no to very small blue peaks, resulting in a clear visual identification of menstrual blood.  306 
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Marker SA1 exhibited significantly saliva-specific hypermethylation (p < 0.001) with an even higher 307 
specificity compared to literature data [21] (Fig.2B). High blue peaks were visible in the electropherograms 308 
in saliva samples with complete lack of methylation or blue peaks in semen and menstrual blood samples.  309 
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Fig. 1 Representative electropherogram of 
the multiplex SNaPshot assay. The blue 
peak (for guanine) shows the methylated and 
the green peak (for adenine) the 
unmethylated portion. From left to right: The 
menstrual blood- specific marker VF2, the 
saliva-specific marker SA1, the semen-
specific marker SE2, and the venous blood-
specific marker BL1.  
 
A shows the developed multiplex SNaPshot 
assay exemplarily for one sample of each 
body fluid sample: semen (A1), saliva (A2), 
venous blood (A3), and menstrual blood of 
the three days of the menses (A4-6). Marker 
VF2 exhibits menstrual blood-specific, 
marker SA1 saliva-specific, and marker SE2 
semen-specific hypermethylation. Marker 
BL1 shows a higher methylation state in 
semen and blood. MB-1, MB-2, MB-3 = 
menstrual blood of days 1, 2, and 3 of the 
menses.  
B shows 1:1 mixtures of bisulfite-converted 
DNA. Partial methylation is exhibited in the 
mixtures of menstrual blood (MB) and semen 
in the menstrual blood-specific marker VF2 
and the semen-specific marker SE2 (B1). 
Partial methylation is exhibited in the 
mixtures of menstrual blood and venous 
blood in the menstrual blood-specific marker 
VF2 and blood-specific marker BL1 (B2). Bis 
= Bisulfite-converted DNA sample 
C shows the analysis of the mock crime 
scene stains. Stain C1 contained venous 
blood and saliva, stain C2 solely saliva, stain 
C3 saliva and semen, stain C4 saliva, semen 
as well as blood, and stain C5 solely venous 
blood. It was possible for the analyst to 
correctly determine the composition of the 
five stains based on analysis of the 
electropherograms. 
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Although numerous venous blood samples (92 %) also expressed a very low level of methylation, they 311 
were distinguishable by visual comparison of peak height: While saliva samples showed >90% 312 
methylation in all samples analyzed, blood revealed <20% methylation in all samples.  313 
Marker SE2 expressed significant semen-specific hypermethylation (p<0.001) with complete lack of 314 
methylation in the remaining body fluids (Fig.2C). Only in semen samples the blue peak, indicating 315 
methylation, was visible while all other body fluids expressed a green peak, indicating no methylation. 316 
Marker BL1 showed a significantly higher methylation state in venous blood compared to saliva, menstrual 317 
blood (p < 0.001) and semen (p < 0.01; Fig.2D). Even though BL1 expresses partial methylation in semen, 318 
a combination of marker BL1 with marker SE2, being hypermethylated in semen and hypomethylated in 319 
venous blood, aids in distinguishing venous blood samples from semen samples.  320 
All markers showed to be highly stable with results from the initial multiplex analyses reliably reproduced 321 
in the final multiplex assay. Not only was the difference in relative methylation amongst the different body 322 
fluids statistically significant but also supported the results from the visual analysis of the 323 
electropherograms. 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
Relative Methylation (%) 
VF2 
        Semen          Saliva          Blood            MB-1            MB-2              MB-3             
  
  
  
  
p < 0.001 (A) 
Relative Methylation (%) 
SA1 
        Semen          Saliva          Blood            MB-1           MB-2              MB-3             
  
p < 0.001 
(B) 
Relative Methylation (%) 
SE2 
         Semen          Saliva          Blood            MB-1           MB-2              MB-3            
  
  
p < 0.001 
  
  
(C) 
Fig. 2 Relative methylation (%) of the multiplex SNaPshot assay. Marker VF2 (A) shows a higher methylation state in menstrual blood 
and nearly complete lack of methylation in all other body fluids (p < 0.001). Marker SA1 (B) exhibits saliva-specific, marker SE2 (C) semen-
specific hypermethylation (p < 0.001). Marker BL1 (D) shows a higher methylation state in venous blood than in saliva, menstrual blood, 
and semen. MB-1, MB-2, MB-3 = menstrual blood of days 1, 2, and 3 of the menses. Circles represent outliers and asterisks represent 
extreme values. 
  
  
  
  
  
p < 0.001 
p < 0.01 
(D) 
BL1 
         Semen          Saliva          Blood            MB-1           MB-2              MB-3            
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3.4 Analysis of body fluid mixtures  335 
Menstrual blood-containing mixtures expressed a significantly higher methylation state in the tDMR for 336 
VF2 than mixtures without menstrual blood (p < 0.001; Fig.S5A). In SA1 the saliva-containing mixtures 337 
expressed a significantly higher methylation state than non-saliva-containing mixtures (p < 0.001; 338 
Fig.S5B). For the mixtures liquid saliva was used while buccal cells were used for the initial testing phase. 339 
The results show that marker SA1 expresses the same methylation profile in liquid saliva and buccal cells. 340 
Semen-containing mixtures expressed a significantly higher methylation state in SE2 than non-semen-341 
containing mixtures (p < 0.001; Fig.S5C). In BL1 (Fig.S5D) the mixture of venous blood and menstrual 342 
blood expressed a significantly higher relative methylation state than the mixtures of semen and saliva (p 343 
< 0.001), menstrual blood and saliva (p < 0.01), and menstrual blood and semen (p < 0.01). The mixture 344 
of venous blood and semen also expressed a significantly higher methylation state than the mixtures of 345 
semen and saliva, menstrual blood and saliva, and menstrual blood and semen (p < 0.001). The mixture 346 
of venous blood and saliva expressed a significantly higher methylation state than the mixture of semen 347 
and saliva (p < 0.001). In figure 1B electropherograms are given exemplarily for two mixtures; menstrual 348 
blood combined with semen (Fig.1B1), and menstrual blood combined with venous blood (Fig.1B2).  349 
 350 
3.5 Analysis of mock crime scene stains  351 
The mock crime scene stains were solely analyzed visually based on electropherograms without the 352 
support of descriptive statistics (Fig.1C). It was possible to correctly determine the composition of 5/5 353 
stains. The correct determination included the definition of whether the stain stemmed from a single 354 
source or a mixture and then, of which body fluids the mixture was generated as well as the determination 355 
of minor and major components within the mixture. Stain C1 contained 2 µl saliva and 10 µl venous blood. 356 
The saliva-specific marker SA1 and the venous blood-specific marker BL1 both expressed partial 357 
methylation with an overall stronger signal in BL1. The menstrual blood-specific marker VF2 as well as the 358 
semen-specific marker SE2 were both hypomethylated. Based on this information it was accurately 359 
determined that the major component of the mixture was venous blood and the minor component saliva. 360 
Stain C2 consisted of 10 µl saliva, and only marker SA1 showed a clear signal for hypermethylation with 361 
all other markers expressing hypomethylation. Accordingly it was correctly concluded that the stain only 362 
consisted of saliva. Stain C3¶VFRPSRQHQWVZHUH 5 µl saliva and 5 µl semen. Markers SA1 and SE2 both 363 
expressed partial methylation with an overall equal signal intensity. Hypomethylation was observed in 364 
PDUNHUV9)DQG%/7KHVWDLQ¶VFRPSRVLWLRQZDVaccurately determined to be of equal parts semen and 365 
saliva. Stain C4 contained 3 µl saliva, 3 µl semen, and 3 µl venous blood. Markers SA1, SE2, and BL1 all 366 
showed to be partially methylated while marker VF2 was hypomethylated. It was therefore determined that 367 
the stain consisted of saliva, semen, and venous blood in equal concentrations. Stain C5 contained 10 µl 368 
venous blood. Marker BL1 showed to be partially methylated, while markers VF2, SA1, and SE2 369 
expressed hypomethylation. The stain was concluded to stem from venous blood only.  370 
 371 
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4. Conclusion 372 
The main advantage of using DNA methylation assays over conventional presumptive tests or RNA based 373 
methods is that it can be applied even after DNA testing. In all other test methods, a decision on whether 374 
or not body fluid identification is necessary needs to be made by the analyst before a DNA typing result 375 
was obtained. Thus, methylation analysis complements conventional presumptive tests because it 376 
enables body fluid identification at a later time point in the investigative process. This can be very helpful 377 
in cases in which the presence of a mixture of body fluids becomes obvious only after DNA typing. While 378 
mRNA analyses were shown to also allow the discrimination of body fluid mixtures [24] the decision for 379 
RNA/DNA co-extraction needs to be made before DNA typing results are available. 380 
The results of this study suggest that a combination of only four highly informative markers will be enough 381 
for clear body fluid identification. The included markers were validated from previous studies and 382 
demonstrated to be robust and reliable in the developed multiplex assay. The multiplex assay aids in the 383 
identification of not only single source body fluids but also of body fluid mixtures. Both markers BL1 and 384 
VF2 allow for the differentiation between venous and menstrual blood. This is especially important in 385 
alleged sexual assault cases as the differentiation between venous and menstrual blood could provide 386 
valuable information regarding the issue of consent. VF2, however, was originally designed as marker for 387 
the detection of vaginal fluid [20]. To also discriminate between mixtures of vaginal fluid with blood and 388 
menstrual blood, further markers with specific methylation states in menstrual blood are needed. Lee et al. 389 
very recently published two potential candidate markers [25] that still need independent validation. Marker 390 
SE2 was shown to be hypermethylated despite the fact that spermatozoa are expected to be 391 
hypomethylated due to epigenetic reprogramming, making marker SE2 even more interesting for semen 392 
identification since it is a rare example of hypermethylation. Marker SA1 expressed saliva-specific 393 
hypermethylation not only in buccal cell swabs but also in liquid saliva. Since it is more likely to encounter 394 
saliva in a forensic setting than buccal cells, this marker can be straightforwardly applied to crime scene 395 
VWDLQVDVVKRZQ LQ WKLVVWXG\2QHPDLQFULWHULD IRUPDUNHUVHOHFWLRQZDV³RQ-/off-PHWK\ODWLRQ´PHDQLQJ396 
hypermethylation in the tissue in question and hypomethylation in all other fluids or vice versa. This leads 397 
to a difference in methylation state that is obvious by visible inspection through analysis of 398 
electropherograms rather than being detectable by application of statistical analysis of large sample sets 399 
only. As the markers SA1, SE2, and VF2 expressed methylation only in their respective body fluids, 400 
marker BL1 showed high methylation levels in venous blood as well as semen samples. Consequently, 401 
BL1 should be used in combination with marker SE2 to exclude semen presence. To this date no venous 402 
blood marker was discovered that expresses strict on-/off-methylation. Although recent studies identified 403 
new markers for potential venous blood identification, those markers also did not express venous blood-404 
specific methylation only [22,23,25], stressing the need for further research towards the discovery of a 405 
venous blood marker that allows for unambiguous identification.  406 
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Table S1 Overview of the 13 markers chosen for singleplex analysis.  
Body fluid Target ID1 Gene CpG sites CpG site2 Marker name3 Source 
Blood cg06379435 n/a 5 chr19:3344273 BL1 Lee et al. [20], Park et al. [19] 
cg01543184  MAFG 14 chr17:79881543 BL2 Lee et al. [20] 
Saliva cg09652652 FAM43A 17 chr3:194408847 SA1 Lee et al. [20] 
 
Menstrual fluid 
cg09765089-231d  n/a 12 chr7:27291577 VF1 Lee et al. [20] 
cg26079753-7d  n/a 9 chr12:54355535 VF2 Lee et al. [20] 
cg15123573 PFN3 12 chr5:176759712 PFN3 Lee et al. [17], An et al. [18] 
n/a PRMT2 7 chr21:46905904 PRMT2 Lee et al. [17], An et al. [18] 
 
 
Semen 
cg17610929  ASIC4 15 chr2:220379044 SE1 Lee et al. [20],  Park et al. [19] 
cg26763284-138u  PLEC 7 chr8:145018185 SE2 Lee et al. [20] 
cg17621389 n/a 6 chr6:147728290 SE3 Lee et al. [20] 
n/a PRMT2 7 chr21:46905904 PRMT2 Lee et al. [17], An et al. [18] 
n/a USP49 19 chr6:41881972 USP49 Lee et al. [17], An et al. [18] 
n/a DACT1 6 chr14:58182894 DACT1 Lee et al. [17], An et al. [18] 
 
1 The TargetID is unique to the Illumina HumanMethylation 450 K bead array used in the studies by Park et al. and  Lee et al. [19,20].  
2 The CpG site is indicated by the genomic location by the human reference genome 37 (GRCh37/hg19). 
3 The marker name was adopted from the according literature [18-21]. 
  
  
Table S2 PCR primers and single-base extension primers for the intitial multiplex testing1. 
Initial Multiplex bisulfite PCR primers  Single-base extension (SNaPshot) primers 
Marker 6HTXHQFH¶!¶ Conc. 
(µM) 
Amplicon 
size (bp) 
6HTXHQFH¶!¶ Conc. 
(µM) 
Amplicon 
size (bp) 
BL1 F:TTTATTGGGGTATTTTTATTGGTTAG 
R:AAAATACAACTTACTCCTAAACACC 
1.5 
1.5 
159 
R:(TG)47CCRATAAAACCTCAAACRTAAAAC 0.36 118 
BL2 
F:GGAGAGGTAGGTTTAGAAGGAAGT 
R:CCCTCACCTACTATTAACCAAACTAAA 
0.8 
0.8 
196 
R:(TG)15CRACTCTCRTAAAACRCTATTAACTAAC 0.36 58 
SA1 
F:GGGGATTYGTTTYGTTAGGT 
R:CCATTTCCCCCTTCCTAAAA 
6.4 
8.0 
153 
R:(GT)13GCCACGAATAAATAACCACGATAAAAC 0.36 53 
SE1 
F:TGTTGATATGTTTTGAATTATTAAG 
R:ATAACTTCCCTTATCAACACCAAC 
0.4 
0.4 
174 
R:(TG)15CCRAAACCCTCCCCAC 0.36 46 
SE2 
F:TGATTTATAATTATTAGGGAGGGAAATAG 
R:CCTAAAACAACCCRATTCCCAAC 
0.2 
0.4 
105 
R:(TG)20CRCRTAACRACTATAAAACCCTC 0.36 63 
SE3 
F:TTTTTATGAATTTTAAGATGGTTAA 
R:ATACCTACCTCAATACTAACCC 
2.0 
2.0 
127 
R:(TG)22ACTTAAAAAAATCRAACAACTTCC 0.36 31 
USP49 F:YGTTTGGGGTTATGGTYGGT 
R:ACACCCCTCCRCRCAAAAAT 
1.1 
1.1 
150 
R:(A)10CRCCRCCACACRCAAACTAC 0.36 30 
DACT1 F:GTTTAGTTTTTTAGGGGTTGGAGAA 
R:TTCTTAAATTTCTTATTTATATCCAAATCA 
1.3 
1.3 
115 
F:(A)15GGTTGGAGAAYGGTTTGTTTAT 0.36 37 
VF1 
F:TTGGTAGTTTTTGGATTTTGGAG 
R:AAACRTAAAACRACCCRAAC 
0.6 
4.8 
137 
R:(TG)5TCCCCAAATAACAAACRACRAAAATC 0.36 36 
VF2 
F:TTTTGTGAGTGTGAGAGATTTTTAAGA 
R:AAAACCTCCAAAACAAAACCTCTA 
0.4 
0.4 
176 
R:(TG)9CRATCAACTACTATAAAAACACC 0.36 41 
PFN3 F GTAAGTGGAGGAGGAGTTAGT 
R:TACATAAAAACATCCTCAACAAAAC 
0.6 
0.6 
147 
R:(A)25RAACCAAATAAACTATAACCTAAACRC 0.36 52 
PRMT2 F:TAATTTTTTAATTGGAAGAGTTGAG 
R:TAAAAAAACCACCCCCAAAAC 
1.0 
1.0 
145 
F:(A)20TTGAGTTGAGYGTYGAAAAGATTT 0.36 43 
 
1 PCR primers are specifically designed for one strand of the bisulfite-converted DNA. In the bisulfite conversion reaction unmethylated cytosine is being converted into uracil and amplified as thymine in 
the PCR. The nucleotide T in the forward (F) and A in the reverse (R) sequence obtained upon bisulfite conversion of unmethylated cytosine is underlined. The nucleotides that are located at the sites 
complementary to methylatable cytosines are indicated in bold as Y or R (wobble bases) for the forward or reverse strand, respectively.   
  
 
Table S3 Multiplex PCR primers and single-base extension primers used for the final methyaltion-sensititve multiplex SNaPshot assay1. 
 
1 PCR 
primers 
are 
specifically 
designed 
for one 
strand of 
the 
bisulfite-
converted 
DNA. In 
the 
bisulfite conversion reaction unmethylated cytosine is being converted into uracil and amplified as thymine in the PCR. The nucleotide T in the forward (F) and A in the reverse (R) sequence obtained upon 
bisulfite conversion of unmethylated cytosine is underlined. The nucleotides that are located at the sites complementary to methylatable cytosines are indicated in bold as Y or R (wobble bases) for the 
forward or reverse strand, respectively.   
Multiplex bisulfite PCR primers Single-base extension (SNaPshot) primers 
Marker 6HTXHQFH¶!¶ Conc. 
(µM) 
Amplicon 
size (bp) 
6HTXHQFH¶!¶ Conc. 
(µM) 
Amplicon 
size (bp) 
BL1 F:TTTATTGGGGTATTTTTATTGGTTAG 
R:AAAATACAACTTACTCCTAAACACC 
12.5 
12.5 
159 R:(TG)22CCRATAAAACCTCAAACRTAAAAC 0.36 68 
SA1 
F:GGGGATTYGTTTYGTTAGGT 
R:CCATTTCCCCCTTCCTAAAA 
53.3 
6.6 
153 R:(GT)13GCCACGAATAAATAACCACGATAAAAC 0.36 53 
SE2 
F:GGGGATTYGTTTYGTTAGGT 
R:CCATTTCCCCCTTCCTAAAA 
0.16 
0.3 
105 R:(TG)20CRCRTAACRACTATAAAACCCTC 0.36 63 
VF2 
F:TGTTGATATGTTTTGAATTATTAAG 
R:ATAACTTCCCTTATCAACACCAAC 
0.3 
0.3 
176 R:(TG)9CRATCAACTACTATAAAAACACC 0.36 41 
  
   
 
 
  
 
Fig. S1 Relative DNA methylation (%) in the tDMRs for the detection of menstrual blood in the multiplex SNaPahot assay. From left to right semen, saliva, venous blood, and menstrual 
blood from day 2 of the menses (=MB-2). The methylation state in PFN3 was significantly lower menstrual blood compared to saliva and venous blood (p < 0.001), and significantly higher than 
in semen (p < 0.01) (A). The tDMR for VF1 expressed statistically highly relevant differences in relative methylation between menstrual blood and semen as well as saliva (p  0.001). No 
statistically relevant differences between states of methylation between menstrual blood and venous blood were detected (B). In VF2 menstrual blood expressed significant hypermethylation 
compared to semen, saliva, and blood (p < 0.001) (C). Marker PRMT2 expressed highly statistically significantly greater methylation in menstrual blood than in semen (p < 0.001). Relative 
methylation in menstrual blood was statistically insignificantly different from relative methylation in saliva and venous blood. Circles represent outliers and asterisks represent extreme values. 
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Fig. S2 Relative DNA methylation (%) in the tDMR for the detection of saliva in the multiplex SNaPahot assay. From left to right semen, saliva, venous blood, and menstrual blood from 
day 2 of the menses (=MB-2). Only in saliva SA1 showed almost complete methylation, while all other body fluids expressed hypomethylation. Differences in relative methylation were highly 
statistically significant (p < 0.001), allowing unambiguous distinguishing between saliva and semen, venous blood, and menstrual blood. Circles represent outliers and asterisks represent 
extreme values. 
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Fig. S3 Relative DNA methylation (%) in the tDMRs for the detection of semen in the multiplex SNaPahot assay. From left to right semen, saliva, venous blood, and menstrual blood from 
day 2 of the menses (=MB-2). Markers SE1 (A) and SE2 (B) expressed significantly semen-specific hypermethylation (p < 0.001). Marker SE2 showed lower intersample variation than SE1. 
Relative methylation for USP49 (C) was significantly lower in semen compared to saliva, menstrual blood, and venous blood (p<0.001). In PRMT2 (D) relative methylation in semen was 
significantly lower than in menstrual blood, venous blood, and saliva (p < 0.001). In  DACT1 (E) semen expressed significantly lower relative methylation than all other body fluids (p < 0.001). 
Circles represent outliers and asterisks represent extreme values. 
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Fig. S4 Relative DNA methylation (%) in the tDMRs for the detection of venous blood in the multiplex SNaPahot assay. From left to right semen, saliva, venous blood, and menstrual 
blood from day 2 of the menses (=MB-2). Marker BL1 (A) expressed significant hypermethylation in venous blood with low to no methylation in all other body fluids (p  0.001). In BL2 (B) saliva 
samples expressed complete unmethylation. Relative methylation in venous blood was significantly higher than in saliva (p < 0.001) and in menstrual blood (p < 0.01) but insignificantly lower 
than in semen. Circles represent outliers and asterisks represent extreme values. 
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Fig. S5 Relative DNA methylation (%) in the tDMRs of body fluid mixtures in the multiplex SNaPahot assay. In VF2 (A) menstrual blood-containing mixtures expressed a significantly 
higher methylation state than non-menstrual-blood-containing mixtures (p < 0.001). In SA1 (B) the saliva-containing mixtures expressed a significantly higher methylation state than non-saliva-
containing mixtures (p < 0.001). In SE2 (C) semen-containing mixtures expressed a significantly higher methylation state non-semen-containing mixtures (p < 0.001). In BL1 (D) the mixture of 
venous blood and menstrual blood expressed a significantly greater methylation state than the mixtures of semen and saliva (p < 0.001), menstrual blood and saliva (p < 0.01), and menstrual 
blood and semen (p < 0.01). The mixture of venous blood and semen also expressed a significantly greater methylation state than the mixtures of semen and saliva, menstrual blood and 
saliva, and menstrual blood and semen (p < 0.001). The mixture of venous blood and saliva expressed a significantly higher methylation state than the mixture of semen and saliva (p < 0.001). 
Circles represent outliers and asterisks represent extreme values. 
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